---
title: "Megan D. Bailey to Resign; Brian J. Caveney Named EVP, President, Biopharma Laboratory Services at Labcorp"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/295939152.md"
description: "Labcorp announced executive changes effective September 2026. Megan D. Bailey will resign as EVP and President, Central Laboratories and International on Sept 4. Brian J. Caveney, M.D., currently EVP and President of Early Development Research Laboratories, will assume the role of EVP and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer on Sept 1, also taking over responsibilities for Central Laboratories businesses."
datetime: "2026-08-14T13:03:13.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/295939152.md)
  - [en](https://longbridge.com/en/news/295939152.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/295939152.md)
generator: "portal-rs"
---

# Megan D. Bailey to Resign; Brian J. Caveney Named EVP, President, Biopharma Laboratory Services at Labcorp

**Labcorp announced that Megan D. Bailey will resign as Executive Vice President and President, Central Laboratories and International, effective September 4, 2026, and that Brian J. Caveney, M.D. will assume the role of Executive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer, effective September 1, 2026.**

**Individual**

Megan D. Bailey

Brian J. Caveney, M.D.

**Role**

Executive Vice President and President, Central Laboratories and International

Executive Vice President and President, Biopharma Laboratory Services and Chief Medical and Scientific Officer

**Type of Change**

Resigned

Appointed / Role change

**Effective Date**

September 4, 2026

September 1, 2026

**Reason**

Not disclosed

Not disclosed

**Replacement Info**

Brian J. Caveney, M.D. will assume responsibilities for Central Laboratories businesses as part of his new role

N/A

**Background Details**

Not disclosed

Current EVP and President, Early Development Research Laboratories and Chief Medical and Scientific Officer; will assume additional responsibilities for Central Laboratories

**Board/Committee Role Changes**

Not disclosed

Not disclosed

Original SEC Filing: LABCORP HOLDINGS INC. \[ LH \] - 8-K - Aug. 14, 2026

**Disclaimer**

This is an AI-powered summary. It may contain inaccuracies. Consider verifying important information with the source. Please note this summary is solely based on documents filed with the SEC.

### Related Stocks

- [LH.US](https://longbridge.com/en/quote/LH.US.md)

## Related News & Research

- [20:00 ETIf you conducted Search Queries on Labcorp's website from May 1, 2021 to April 1, 2026, a class action settlement may affect you](https://longbridge.com/en/news/298081839.md)
- [Labcorp to host investor day webcast, outlines strategy and long-term outlook update](https://longbridge.com/en/news/296102211.md)
- [BioAge Labs to present at Citi Biopharma Back to School Conference fireside chat](https://longbridge.com/en/news/297782949.md)
- [Lexicon to present at Citi Biopharma Back to School investor conference](https://longbridge.com/en/news/297692441.md)
- [Redhill Biopharma Stock Doubles In One Session — Here's Why](https://longbridge.com/en/news/297531464.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**